CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd.

1:23-cv-00026

Overview

Case Number 1:23-cv-00026
Filing Date 2023-01-11
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

CANDA HEC-1, LLC Operating Company

Represented By

6 Attorneys Listed

Steven J. Udick

Email: sudick@skiermontderby.com

Sarah E. Spires

Email: sspires@skiermontderby.com

Paul J. Skiermont

Email: pskiermont@skiermontderby.com

Mieke K. Malmberg

Email: mmalmberg@skiermontderby.com

Kevin P. Potere

Email: kpotere@skiermontderby.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Plaintiff

Novartis Pharmaceuticals Corporation Operating Company

Represented By

2 Attorneys Listed

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Counter Claimant

Rising Pharma Holdings, Inc. NPE (Patent Assertion Entity)

Represented By

6 Attorneys Listed

Steven J. Udick

Email: sudick@skiermontderby.com

Sarah E. Spires

Email: sspires@skiermontderby.com

Paul J. Skiermont

Email: pskiermont@skiermontderby.com

Mieke K. Malmberg

Email: mmalmberg@skiermontderby.com

Kevin P. Potere

Email: kpotere@skiermontderby.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Sunshine Lake Pharma Co., Ltd. Operating Company

Represented By

1 Attorneys Listed

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

HEC Pharm USA Inc. Operating Company

Represented By

6 Attorneys Listed

Steven J. Udick

Email: sudick@skiermontderby.com

Sarah E. Spires

Email: sspires@skiermontderby.com

Paul J. Skiermont

Email: pskiermont@skiermontderby.com

Mieke K. Malmberg

Email: mmalmberg@skiermontderby.com

Kevin P. Potere

Email: kpotere@skiermontderby.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

HEC Pharm Co., Ltd. Operating Company

Represented By

6 Attorneys Listed

Steven J. Udick

Email: sudick@skiermontderby.com

Sarah E. Spires

Email: sspires@skiermontderby.com

Paul J. Skiermont

Email: pskiermont@skiermontderby.com

Mieke K. Malmberg

Email: mmalmberg@skiermontderby.com

Kevin P. Potere

Email: kpotere@skiermontderby.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials Counterparts in force
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): ๐Ÿ‡บ๐Ÿ‡ธ US ๐ŸŒ PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US10543179
Dosage regimen of an S1P receptor modulator
Filed: 2018-05-23
Issued: 2020-01-28
Active (11.5 yrs remaining)
Expires: 2038-05-23

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. ยง 283) Active Threat

Active Threat โ€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term โ€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. ยง 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

16

Dispositive

10

Granted

0

Denied

1

Pending / Review

11

Motions by Category

Procedural / Extension Motion 6 Motion to Dismiss (FRCP 12(b)(6)) 4 Motion to Dismiss 5 Motion to Dismiss (35 U.S.C. ยง 101 / Alice) 1

Key Dispositive Motions & Rulings

Motion to Dismiss (35 U.S.C. ยง 101 / Alice) Denied
ORAL ORDER: Defendants' Motion to Dismiss for Failure to State a Claim (No. 23-26, D.I. 12, 14, 15, 19, 20, 23) is DENIED. On this record, the Court does not vi...
Entry #26 • 2024-03-12 Document →
Motion to Dismiss Pending / Under Review
STIPULATION and [Proposed] Order Regarding Case Consolidation and Pending Motion to Dismiss by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered...
Entry #25 • 2023-08-25 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
REPLY BRIEF re 12 MOTION to Dismiss for Failure to State a Claim filed by CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Ent...
Entry #23 • 2023-07-13 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
[SEALED] ANSWERING BRIEF in Opposition re 12 MOTION to Dismiss for Failure to State a Claim filed by Novartis Pharmaceuticals Corporation.Reply Brief due date p...
Entry #19 • 2023-06-29 Document →
Motion to Dismiss Pending
SO ORDERED, re 17 STIPULATION TO EXTEND TIME to reply to Defendants HEC Pharm Co., Ltd., HEC Pharm USA Inc., CANDA HEC-1, LLC, and Rising Pharma Holdings, Inc.,...
Entry #โ€” • 2023-06-16
Motion to Dismiss Pending / Under Review
STIPULATION TO EXTEND TIME to reply to Defendants HEC Pharm Co., Ltd., HEC Pharm USA Inc., CANDA HEC-1, LLC, and Rising Pharma Holdings, Inc., d/b/a Rising Phar...
Entry #17 • 2023-06-14 Document →

Docket Entries

(60 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against CANDA HEC-1, LLC, HEC Pharm Co., Ltd., HEC Pharm USA Inc., Rising Pharma Holdings, Inc., Sunshine Lake Pharma Co., Ltd. ( Filing fee $ 402, receipt number ADEDC-4041634.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 01/11/2023)

Entry #1 • 2023-01-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 01/11/2023)

Entry #2 • 2023-01-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,543,179. (twk) (Entered: 01/11/2023)

Entry #3 • 2023-01-11
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (twk) (Entered: 01/11/2023)

Entry #4 • 2023-01-11
1

No Summons Issued

Entry #5 • 2023-01-11
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc